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and anti-G3 quantitative Western blot showed aggrecan fragment
patterns for individual subjects, allowing a detailed comparison
of aggrecan proteolysis in different human joint diseases and dis-
ease stages. SF aggrecan fragment patters differed signiﬁcantly
between different human joint diseases, suggesting differences
in protease activity and or structure of the cartilage matrix sub-
strate. Use of additional antibodies will allow quantiﬁcation of
other aggrecan fragments. The method can help identify new OA
biomarkers. It is also suitable for in vitro screening of protease
inhibitors and in early development of disease modifying therapy
of human joint diseases.
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Purpose: Biochemical markers (BM) may be useful to assess
disease progression and efﬁcacy of treatments in osteoarthritis
(OA). The clinical utility of BMs depends on two components: 1)
their sensitivity to detect changes with disease or treatment and
2) their biological variability which may be affected by food intake.
The aim of this study was to evaluate the effect of food intake on
the concentration and the between day intra-subject variability of
BMs in untreated patients with knee OA and in healthy subjects
of similar age.
Methods: We recruited 22 patients (13 women, 9 men, mean
age 58 yr) with radiographic knee OA (12 with Kellgren-Lawrence
[KL] score 2 and 10 with KL score 3) and 10 healthy subjects
(7 women, 3 men, mean age: 47 yr) with no radiographic OA
at the knees, hips and spine. No subject was treated with any
investigational OA drugs, estrogen or bisphosphonate within the
previous 3-6 months and during the 14 days study period. When
receiving NSAIDs and/or dietary supplements, no change in
therapy was permitted during the study. For each subject and
at each of the 3 visits (day 1, day 7 and day 14), morning
blood samples were collected at two time points: fasting (F) at
7.45 before an 8.00 breakfast and non-fasting (NF) at 10.00,
2 hours after breakfast. Second morning void urine was also
collected at each 3 visits. The following serum (S) and urine
(U) BMs were measured: S-CTX-I, a BM of bone resorption,
S-COMP, a BM of cartilage turnover, S-PIIANP, a BM of cartilage
synthesis, hyaluronic acid (S-HA), a BM of synovitis, U-CTX-II,
a BM of cartilage degradation and U-Glc-Gal-PYD, a BM of
synovial tissue metabolism. For S-BMs, the difference in levels
between NF and F state was calculated and the intra-subject
variability was estimated by mixed model ANOVA.
Results: Patients with knee OA had higher median levels of S-
COMP (+30%, p=0.02 and +24%, p=0.05 for F and NF samples,
respectively), S-HA (+48%, p=0.02 and +13%, p=0.12 for F
and NF samples) and CTX-II (+108%, p<0.01) than healthy
controls. Patients with knee OA KL score 3 had higher F-levels
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S-CTX-I S-COMP S-PIIANP S-HA
% NF-F CVi-F CVi-NF %NF-F CVi -F CVi -NF % NF-F CVi -F CVi -NF % NF-F CVi -F CVi-NF
All -52%** 12.9 28.6 0.1% 8.8 8.8 -2.0% 19.7 25.1 +33%** 34.3 34.2
Knee OA -52%** 12.5 29.8 -0.1% 8.5 8.9 -1.9% 19.6 25.7 +30%** 36.1 37.0
Healthy -51%* 13.0 23.9 0.4% 9.2 8.0 -8.9% 20.4 20.6 +45%* 19.7 22.0
*p<0.01, **p<0.001.
of S-CTX-I (+64%, p=0.02), S-COMP (+37%, p=0.02), S-HA
(+68%, p=0.03), U-CTX-II (+151%, p<0.001) and U-Glc-Gal-
PYD (+53%, p=0.01) than patients with KL-2. When measured
on NF samples, the difference between patients with KL-2 and
KL-3 was not anymore signiﬁcant for S-CTX-I and S-HA. The
table shows the difference of S-BM levels in NF compared with F
state as a percentage (% NF-F) and the intra subject coefﬁcient
of variation (CVi%) in all subjects, in patients with knee OA, and
in healthy controls and in F (CVi-F) and NF (CVi-NF) conditions.
For urinary markers, the intra-subject variability in all subjects,
knee OA patients and healthy controls were respectively 23.1%,
19.6% and 30.5% for U-CTX-II and 21.1%, 22.3% and 16.4% for
U-Glc-Gal-PYD.
Conclusions: Food intake has a marked inﬂuence on the levels
of S-CTX-I and S-HA and increases variability of S-CTX-I, but has
small effects on S-COMP and S-PIIANP. The association of S-
BMs with OA was higher when measured on F than NF samples.
Standardized collection of fasting sample is recommended for
measuring BM in OA.
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Purpose: Rheumatoid Arthritis (RA) is a chronic auto-immune
disease with aggressive and extensive articular cartilage destruc-
tion. Aggrecan is the major proteoglycan of articular cartilage,
and is composed of three globular domains (G1-G3). Aggrecan
depletion, mediated by aggrecanases is one of the ﬁrst signs of
early cartilage erosion. We investigated, whether measurement
of aggrecan and fragments thereof in serum, could be used as
biomarkers for joint-disease in RA patients.
Methods: For the veriﬁcation of release of intact aggrecan and
degradation fragments, we used catabolically stimulated human
cartilage explants from a late stage 42 year old female patient
with osteoarthritis (OA). Pieces of cartilage (12-16 mg) were
placed in 96 well plates in 4-replicates and incubated for 21
days at 37°C with 5% CO2 and shaking (50 rpm). Serum-free
D-MEM medium was used. Explants were incubated with either
medium alone, or 10 and 20 ng/ml of the pro-inﬂammatory
cytokines OSM/TNFα respectively. As negative control, cartilage
was placed in cryo-tubes, frozen in liquid N2 and thawed at 37°C
in water-bath for three repeated freeze-thaw cycles. The explant
culture medium was replaced every 3rd day for 21 days.
The study co-hort consisted of 108 healthy individuals and 38
patients diagnosed with RA (61.3±19.3 years, 71.05 ±14.5
kg, 4.7±1.6 disease activity score). Aggrecan levels were in-
vestigated by, 1) 374ARGSVI-G2 sandwich assay measuring
aggrecanase-mediated aggrecan degradation, or 2) G1/G2 sand-
wich assay, believed to account for the total turnover of aggre-
can. We further characterised serum samples by western blots,
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through 1) the similar antibody used in the G1/G2 ELISA assay,
F-78, binding to a repetitive epitope exposed twice on G1 and G2
or, 2) by BC-3 detecting the aggrecanase-generated N-terminal
374ARGSVI sequence.
Results: Induction of cartilage degradation ex vivo, resulted in 10
fold elevated aggrecanase fragments (374ARGSVI-G2) (P=0.02)
and 9 fold increased total aggrecan release (G1/G2) (P=0.02),
compared to that of vehicle control. Total aggrecan levels in
RA patients were signiﬁcantly decreased from 824.8±31 ng/ml
in healthy controls to 570.5±30 ng/ml, corresponding to an
approximate 31% decrease (P<0.0001). Western blot analysis
for total aggrecan showed one strong band detected at 10 kDa,
and weaker bands at 25 and 45 kDa in both healthy controls
and RA patients. With regards to aggrecanase activity, only one
strong band in RA patients of 45 kDa was detected.
Conclusions: This study is the ﬁrst to characterize different
aggrecan fragments in human serum. We clearly demonstrate
that total aggrecan levels are lowered in RA patients. In align-
ment, RA patients had highly elevated aggrecanase-mediated
aggrecan degradation, providing a rationale for the decreased
aggrecan levels. These data may provide a new diagnostic tool
for monitoring joint-destruction in RA patients, and allow for early
assessment of response to treatment prior to that of traditional
radiographic techniques.
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CLEAVAGE PRODUCTS OF HUMAN ARTICULAR
CARTILAGE
I.J. Brittain1, E.Y. Zhen1, D.A. Laska1, J.E. Hale1,
P.G. Mitchell2, K.L. Dufﬁn1
1Eli Lilly and Company, Greenﬁeld, IN; 2Eli Lilly and Company,
Indianapolis, IN
Purpose: The present study measures the effects of metallopro-
teases on human articular cartilage. Supernatants from diges-
tions with these enzymes were analyzed via proteomics methods
to characterize post-translational modiﬁcations of cartilage pep-
tides, to determine speciﬁc cartilage protein cleavage sites of
different metalloproteases to better understand their selectivities,
and to measure release of peptides that may serve as useful
biomarkers of cartilage degradation. The metalloproteases uti-
lized in this study have been reported to be overexpressed and
active in arthritic cartilage, so determination of their substrates
and products may lead to a better understanding of their po-
tential role in disease and to identiﬁcation of new targets and
biomarkers of cartilage degradation.
Methods: Human articular cartilage was digested by addition
of exogenous metalloproteases, including MMP-2, -3, -8, -9, -
12, -13, ADAMTS-4, and ADAMTS-5, and proteolyzed peptide
products were identiﬁed by proteomics methods using mass
spectrometry.
Results: Complete sequences of peptides, including N- and
C-termini and post-translational modiﬁcations were determined.
Abundant peptides originating from collagen types I, II, and III,
biglycan, prolargin, ﬁbromodulin, ﬁbronectin, decorin, cartilage
oligomeric matrix protein, cartilage intermediate layer protein,
megakaryocyte stimulating factor, mimecan, aggrecan, and lu-
mican were identiﬁed after metalloprotease digestion. Speciﬁc
collagen type II peptide biomarkers, including those containing
the 3/4 – 1/4 cleavage site and those containing the Helix-II
and CTX-II domains, were observed after release by selected
proteases.
Conclusions: this study identiﬁes many of the most abundant
metalloprotease cleavage products of human articular cartilage.
The list of peptides generated by these digestions provides in-
sights into the broad number of substrates susceptible to speciﬁc
metalloprotease proteolysis in diseased cartilage. Many of these
peptides are potential biomarkers of arthritis or of metallopro-
tease activity in articular cartilage. Further evaluation of many of
these peptides as biomarkers might be achieved by quantitation
in synovial ﬂuid, blood, or urine.
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Purpose: Collagen type II is the predominant collagen in articular
cartilage and is highly speciﬁc for this tissue. A biomarker of
crosslinked C-telopeptide fragments of type II collagen (CTX II)
has been used to assess severity and progression of cartilage
degradation in humans. The objectives of the current study were
to evaluate the effects of exercise and osteochondral (OC) injury
on concentrations of CTX II fragments in synovial ﬂuid (SF) and
serum of horses.
Methods: SF and serum samples were taken from 3 groups of
Thoroughbred racehorses: (1) rested horses (n=40), (2) exer-
cised horses: group 1 horses had the same joints sampled after
4-7 months of race training (n=40) and (3) OC injured horses:
racehorses that had arthroscopic surgery for removal of OC frag-
ments resulting from racing injury (n=44). From group 1 and 2
horses, SF was obtained from 20 metacarpophalangeal (MCP),
Figure 1. Comparison of SF to serum CTX II concentrations (SF:serum) in
rested, exercised, and OC injured horses. A. MCJ - middle carpal joint; B. RCJ
- radiocarpal joint; C. MCP/MTP - metacarpophalangeal/metatarsophalangeal
joint.
